A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Detrital zircon geochronology is a scientific technique for understanding the age and provenance of sedimentary deposits. To determine the age of zircons deposited within a specific sedimentary unit, mass spectrometry is used to measure the abundance of radioisotopes in the grains, most commonly the uranium–lead ratio. Zircon is a common accessory or trace mineral constituent of most granite and felsic igneous rocks. Due to its hardness, durability and chemical inertness, zircon persists in sedimentary deposits and is a common constituent of most sands. Zircons contain trace amounts of uranium and thorium and can be dated using several modern analytical techniques. Detrital zircon geochronology has become increasingly popular in geological studies from the 2000s mainly due to the advancement in radiometric dating techniques. Detrital zircon age data can be used to constrain the maximum depositional age, determine provenance, and reconstruct the tectonic setting on a regional scale.
DNP raises energy expenditure by 30 to 40 percent and causes a weight loss of 0.7–0.9 kilograms (1.5–2.0 lb) per week. Although DNP is no longer in clinical use as a weight loss drug due to its dangerous side effects, its mechanism of action remains under investigation as a potential approach for treating obesity and non-alcoholic fatty liver disease. Researchers developed a prodrug, HU6, which is metabolized to DNP in the liver to provide more stable blood concentrations. HU6 completed a phase II trial in which it produced significant reductions in liver fat and body weight in overweight people with elevated liver fat, without serious adverse effects. DNP is used by bodybuilders, fitness enthusiasts, and people with an eating disorder to lose weight. The user profile is similar to that of anabolic steroids; many perceive it to be effective and with manageable risks. Despite health warnings from regulators, DNP is readily available online sometimes under other names such as Dinosan, Dnoc, Solfo Black, Nitrophen, Aldifen, and Chemox. DNP is often sold in tablets containing 100 to 200 mg and may be sold alongside other substances such as anabolic steroids and thyroxine. It may also be found as a contaminant in other bodybuilding supplements not advertised as containing DNP. Online message boards provide information on dosage and regimens for DNP use, and describe the risks of taking the compound and provide advice on how to mitigate hyperthermia. According to a study published in 2023, the most commonly reported doses were between 150 to 300 mg/d.
The laurel leaves in the coat of arms of Kaskinen, Finland (Swedish: Kaskö), may have been meant to refer to local flowering, but its origin may also be in the name of the family Bladh (Swedish: blad; 'leaf'); two members of the family – a father and a son – acquired both town rights and the status of staple town for the village at the time.
Sources: en.wikipedia.org
== Bulk properties == Radium is the heaviest known alkaline earth metal and is the only radioactive member of its group. Its physical and chemical properties most closely resemble its lighter congener, barium. Pure radium is a volatile, lustrous silvery-white metal, even though its lighter congeners calcium, strontium, and barium have a slight yellow tint. Radium's lustrous surface rapidly becomes black upon exposure to air, likely due to the formation of radium nitride (Ra3N2). Its melting point is either 700 °C (1,292 °F) or 960 °C (1,760 °F) and its boiling point is 1,737 °C (3,159 °F); however, this is not well established. Both of these values are slightly lower than those of barium, confirming periodic trends down the group 2 elements. Like barium and the alkali metals, radium crystallizes in the body-centered cubic structure at standard temperature and pressure: the radium–radium bond distance is 514.8 picometers. Radium has a density of 5.5 g/cm3, higher than that of barium, and the two elements have similar crystal structures (bcc at standard temperature and pressure).
== External links == GeneReviews/NCBI/NIH/UW entry on Familial Exudative Vitreoretinopathy, Autosomal Dominant This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Twelve days later the 6th Division held a victory parade of its 1,200 guns, tanks and other vehicles at Monza racetrack, 16 kilometres (9.9 mi) north of Milan. The Rhodesians separated from their vehicles after the parade, then spent May and June 1945 as occupation troops in Lombardy before returning home.
=== ICD-11 === Fibromyalgia is not listed as a code in the ICD-11. "Fibromyalgia syndrome" is listed as an inclusion in the ICD-11 code of "Chronic widespread pain" (CWP) (code MG30.01). (No other signs or symptoms of fibromyalgia are mentioned.)
Sources: en.wikipedia.org
Duffy announced later that year that work would begin in 2027 and would cost $7 billion, and in May 2026 Amtrak selected out of three finalists a joint venture of Skanska and Halmar International as developer and Vishaan Chakrabarti's Practice for Architecture and Urbanism (PAU) as lead design architect. The approved plan would keep Madison Square Garden in place and rebuild the passenger facilities beneath it. In June 2026, Amtrak and Penn Transformation Partners released renderings for an approximately $8 billion redesign of Penn Station that would retain Madison Square Garden while creating a larger, light-filled station inspired by the original Pennsylvania Station. Later that month, a pre-development agreement (PDA) was finalized, with the project estimated to break ground by the end of 2027. Amtrak also offered to re-add the MTA as a partner in the station's reconstruction, but the MTA declined.
==== 3.A. P-P-bond hydrolysis-driven transporters ==== 3.A.1 ABC transporters including BtuCD, molybdate uptake transporter, Cystic fibrosis transmembrane conductance regulator and others 3.A.2 The H+- or Na+-translocating F-type ATPase, V-type ATPase and A-type ATPase superfamily 3.A.3 The P-type ATPase Superfamily 3.A.4 The Arsenite-Antimonite efflux family 3.A.5 General secretory pathway (Sec) translocon (preprotein translocase SecY) 3.A.6 The Type III (Virulence-related) Secretory Pathway (IIISP) Family 3.A.7 The Type IV (Conjugal DNA-Protein Transfer or VirB) Secretory Pathway (IVSP) Family 3.A.8 The Mitochondrial Protein Translocase (MPT) Family 3.A.9 The Chloroplast Envelope Protein Translocase (CEPT or Tic-Toc) Family 3.A.10 H+, Na+-translocating Pyrophosphatase family 3.A.11 The Bacterial Competence-related DNA Transformation Transporter (DNA-T) Family 3.A.12 The Septal DNA Translocator (S-DNA-T) Family 3.A.13 The Filamentous Phage Exporter (FPhE) Family 3.A.14 The Fimbrilin/Protein Exporter (FPE) Family 3.A.15 The Outer Membrane Protein Secreting Main Terminal Branch (MTB) Family 3.A.16 The Endoplasmic Reticular Retrotranslocon (ER-RT) Family 3.A.17 The Phage T7 Injectisome (T7 Injectisome) Family 3.A.18 The Nuclear mRNA Exporter (mRNA-E) Family 3.A.19 The TMS Recognition/Insertion Complex (TRC) Family 3.A.20 The Peroxisomal Protein Importer (PPI) Family 3.A.21 The C-terminal Tail-Anchored Membrane Protein Biogenesis/ Insertion Complex (TAMP-B) Family 3.A.22 The Transcription-coupled TREX/TAP Nuclear mRNA Export Complex (TREX) Family 3.A.23 The Type VI Symbiosis/Virulence Secretory Pathway (VISP) Family 3.A.24 Type VII or ESX Protein Secretion System (T7SS) Family 3.A.25 The Symbiont-specific ERAD-like Machinery (SELMA) Family 3.A.26 The Plasmodium Translocon of Exported proteins (PTEX) Family
== Disease associations == The vast majority of patients with positive HLA-B27 will not develop an associated syndrome. The relationship between HLA-B27 and many diseases has not yet been fully elucidated. Though HLA-B27 is associated with a wide range of pathology, it does not appear to be the sole mediator in the development of disease. 90% of people with ankylosing spondylitis (AS) are HLA-B27 positive, although only a small fraction of people with HLA-B27 will develop AS. People who are HLA-B27 positive are more likely to experience early onset AS than HLA-B27 negative individuals. Research is uncovering other genes that predispose to AS and associated diseases, and there are potential environmental factors that may play a role in susceptible individuals. Approximately 40–50% of individuals with psoriatic arthritis have the HLA-B27 genotype. HLA-B27 is implicated in other types of seronegative spondyloarthropathy, such as reactive arthritis, acute anterior uveitis, iritis, Crohn's disease, and ulcerative colitis associated spondyloarthritis. The shared association with HLA-B27 leads to increased clustering of these diseases. HLA antigens have been studied in relation to autism.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.